Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer

Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer

Background: Bevacizumab is an anti-VEGF, humanized mAb that is the most advanced agent of its class in clinical development. Several studies have examined bevacizumab in combination with chemotherapy in the first- and second-line settings in patients with metastatic CRC. Despite of that, there is la...

Full description

Bibliographic Details
Main Authors: Popov Ivan, Tarabar Dino, Jovanović Dušan, Kovčin Vladimir, Radić Stojan, Micev Marjan, Petrović Zoran, Manojlović Nebojša, Andrić Zoran, Dagović Aleksandar, Kukić Biljana, Radoševic-Jelić Ljiljana, Kecmanović Dragutin, Josifovski Jeremija, Jezdić Svetla
Format: Article
Language:English
Published: Institute of Oncology, Sremska Kamenica, Serbia 2007-01-01
Series:Archive of Oncology
Subjects:
antibodies
monoclonal
angiogensis inhibitors
colorectal neoplasms
treatment outcome
antineoplastic combined chemotherapy protocols
vascular endothelial growth factor A + antagonists and inhibitors
Online Access:http://www.doiserbia.nb.rs/img/doi/0354-7310/2007/0354-73100702010P.pdf

Internet

http://www.doiserbia.nb.rs/img/doi/0354-7310/2007/0354-73100702010P.pdf

Similar Items